LASA SUPERGENERICS
|
LASA SUPERGENERICS Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -7.71 | -1.06 | 5.60 | 0.89 | -5.26 |
| CEPS(Rs) | -5.03 | 1.83 | 9.49 | 5.16 | 3.18 |
| DPS(Rs) | - | 0.25 | 0.25 | - | - |
| Book NAV/Share(Rs) | 23.61 | 31.51 | 39.07 | 34.78 | 46.05 |
| Tax Rate(%) | 8.62 | 13.16 | 22.76 | 23.39 | 25.29 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -5.09 | 11.68 | 23.33 | 17.91 | 6.52 |
| EBIT Margin(%) | -29.38 | -4.43 | 15.59 | 7.69 | -4.55 |
| Pre Tax Margin(%) | -32.62 | -4.48 | 14.57 | 2.83 | -9.50 |
| PAT Margin (%) | -29.81 | -3.89 | 11.25 | 2.17 | -7.09 |
| Cash Profit Margin (%) | -19.45 | 6.69 | 19.07 | 12.53 | 4.29 |
| Performance Ratios | |||||
| ROA(%) | -20.71 | -2.56 | 10.43 | 1.50 | -4.44 |
| ROE(%) | -27.97 | -3.37 | 15.17 | 2.94 | -10.81 |
| ROCE(%) | -23.94 | -3.41 | 17.14 | 6.77 | -3.73 |
| Asset Turnover(x) | 0.69 | 0.66 | 0.93 | 0.69 | 0.63 |
| Sales/Fixed Asset(x) | 0.56 | 0.60 | 0.91 | 0.78 | 0.82 |
| Working Capital/Sales(x) | -36.94 | 6.36 | 8.51 | -3,684.39 | -7.97 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.78 | 1.68 | 1.10 | 1.29 | 1.22 |
| Receivable days | 29.63 | 44.35 | 31.94 | 54.04 | 76.45 |
| Inventory Days | 35.78 | 38.27 | 39.28 | 63.18 | 79.46 |
| Payable days | 45.30 | 59.24 | 75.46 | 180.10 | 153.49 |
| Valuation Parameters | |||||
| PER(x) | - | - | 10.70 | 31.83 | - |
| PCE(x) | -3.67 | 22.76 | 6.31 | 5.51 | 7.24 |
| Price/Book(x) | 0.78 | 1.32 | 1.53 | 0.82 | 0.50 |
| Yield(%) | - | 0.60 | 0.42 | - | - |
| EV/Net Sales(x) | 0.86 | 1.55 | 1.28 | 0.94 | 0.79 |
| EV/Core EBITDA(x) | -23.53 | 13.00 | 5.46 | 5.23 | 11.62 |
| EV/EBIT(x) | -2.94 | -34.88 | 8.20 | 12.28 | -17.44 |
| EV/CE(x) | 0.68 | 1.01 | 1.24 | 0.69 | 0.53 |
| M Cap / Sales | 0.71 | 1.52 | 1.20 | 0.69 | 0.31 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -5.51 | -32.24 | 21.00 | -1.37 | -30.37 |
| Core EBITDA Growth(%) | -129.18 | -65.60 | 56.89 | 160.58 | -74.10 |
| EBIT Growth(%) | -526.76 | -119.25 | 145.38 | 266.60 | -129.04 |
| PAT Growth(%) | -624.41 | -123.41 | 527.76 | 130.16 | -197.49 |
| EPS Growth(%) | -624.41 | -119.00 | 527.76 | 116.95 | -197.49 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.18 | 0.13 | 0.12 | 0.34 | 0.80 |
| Current Ratio(x) | 0.92 | 1.48 | 1.59 | 1.00 | 0.80 |
| Quick Ratio(x) | 0.59 | 1.22 | 1.16 | 0.65 | 0.51 |
| Interest Cover(x) | -9.08 | -93.74 | 15.28 | 1.58 | -0.92 |
| Total Debt/Mcap(x) | 0.24 | 0.12 | 0.08 | 0.42 | 1.61 |
Compare Financial Ratios of peers of LASA SUPERGENERICS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LASA SUPERGENERICS | ₹127.9 Cr | 4% | 11% | 2.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,831.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
| CIPLA | ₹113,471.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,713.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,960.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,687.8 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics | |
LASA SUPERGENERICS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LASA SUPERGENERICS | 4% |
11% |
2.4% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
